Lyra Therapeutics (LYRA) Change in Acquisitions & Divestments (2023 - 2024)
Quarterly Change in Acquisitions & Divestments fell 41.62% to $28.1 million in Q4 2024 from the year-ago period, while the trailing twelve-month figure was $130.6 million through Dec 2024, up 17.77% year-over-year, with the annual reading at $130.6 million for FY2024, 17.77% up from the prior year.
Lyra Therapeutics' Change in Acquisitions & Divestments history spans 2 years, with the latest figure at $28.1 million for Q4 2024.
- Change in Acquisitions & Divestments came in at $28.1 million for Q4 2024, up from $21.0 million in the prior quarter.
- In the past five years, Change in Acquisitions & Divestments ranged from a high of $51.0 million in Q2 2024 to a low of $9.8 million in Q1 2023.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,384,976.65 Bn | 1,384,976.64 Bn | - |
| 2 | Alterity Therapeutics | 777,208.84 Bn | 777,208.81 Bn | - |
| 3 | Legend Biotech | 2,801.00 Bn | 2,800.10 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - |
| 5 | Akari Therapeutics | 605.66 Bn | 605.66 Bn | - |
| 6 | Vertex Pharmaceuticals | 110.17 Bn | 102.92 Bn | 2.59 Bn |
| 7 | Regeneron Pharmaceuticals | 66.86 Bn | 58.11 Bn | 3.31 Bn |
| 8 | Evaxion A | 65.12 Bn | 65.10 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.94 Bn | 36.94 Bn | 959.66 Mn |
| 10 | Lyra Therapeutics | - | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 28.07 Mn |
| Dec 31, 2024 | 28.07 Mn |
| Sep 30, 2024 | 21.00 Mn |
| Sep 30, 2024 | 21.00 Mn |
| Jun 30, 2024 | 50.99 Mn |
| Jun 30, 2024 | 50.99 Mn |
| Mar 31, 2024 | 30.53 Mn |
| Mar 31, 2024 | 30.53 Mn |
| Dec 31, 2023 | 48.09 Mn |
| Dec 31, 2023 | 48.09 Mn |
| Sep 30, 2023 | 28.00 Mn |
| Sep 30, 2023 | 28.00 Mn |
| Jun 30, 2023 | 25.00 Mn |
| Jun 30, 2023 | 25.00 Mn |
| Mar 31, 2023 | 9.80 Mn |
| Mar 31, 2023 | 9.80 Mn |